1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Sarilumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Sarilumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Summary

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Regeneron and Sanofi’s sarilumab is the first fully-human mAb against IL-6, and is in Phase III of development for RA. Sarilumab is directed against IL-6R and reduces inflammation, thus preventing the joint damage that is common in RA. Although Actemra is an anti-IL6 mAb currently approved for RA, this biologic agent is a recombinant human mAb and does not offer the same safety advantages of a fully-human mAb.

Scope

- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Sarilumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Sarilumab for the top 8 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Sarilumab performance.
- Obtain sales forecast for Sarilumab from 2013-2023 in top 8 countries (the US, France, Germany, Italy, Spain, the UK and Japan and Australia).

Table Of Contents

Sarilumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
1 Table of Contents
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
2.3 Upcoming Related Reports 14
3 Disease Overview 15
3.1 Etiology and Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology 15
3.2 Symptoms 20
3.3 Prognosis 21
3.4 Quality of Life 21
4 Disease Management 22
4.1 Diagnosis and Treatment Overview 22
4.1.1 Diagnosis 22
4.1.2 Treatment Guidelines 24
4.1.3 Leading Prescribed Drugs for the Treatment of RA 34
4.1.4 Clinical Practice 35
5 Competitive Assessment 41
5.1 Overview 41
6 Unmet Need and Opportunity 43
6.1 Overview 43
6.2 Development of Cost-Effective Therapies 44
6.2.1 Unmet Need 44
6.2.2 Gap Analysis 45
6.2.3 Opportunity 45
6.3 Biomarkers to Predict Responsiveness to Therapy 45
6.3.1 Unmet Need 45
6.3.2 Gap Analysis 47
6.3.3 Opportunity 48
6.4 Early Diagnosis of RA 48
6.4.1 Unmet Need 48
6.4.2 Gap Analysis 49
6.4.3 Opportunity 50
6.5 Personalized Treatment Approach 51
6.5.1 Unmet Need 51
6.5.2 Gap Analysis 51
6.5.3 Opportunity 53
7 Pipeline Assessment 55
7.1 Overview 55
7.2 Promising Drugs in Clinical Development 55
8 Sarilumab 63
8.1 Overview 63
8.2 Efficacy 64
8.3 Safety 66
8.4 Dosing and Formulation 66
8.5 Potential Clinical Positioning 67
8.6 Potential Commercial Positioning 67
8.7 Pricing and Reimbursement 68
8.8 SWOT Analysis 69
8.9 Forecast 69
9 Appendix 71
9.1 Bibliography 71
9.2 Abbreviations 75
9.3 Methodology 78
9.4 Forecasting Methodology 78
9.4.1 Diagnosed RA Patients 78
9.4.2 Percentage of Drug-Treated Patients 79
9.4.3 General Pricing Assumptions 79
9.4.4 Generic and Biosimilar Erosion 80
9.4.5 Pricing of Pipeline Agents 80
9.5 Primary Research - KOLs Interviewed for This Report 81
9.6 Primary Research - Prescriber Survey 83
9.7 About the Authors 84
9.7.1 Analyst 84
9.7.2 Reviewer 84
9.7.3 Therapy Area Director 84
9.7.4 Global Head of Healthcare 85
9.8 About GlobalData 86
9.9 Disclaimer 86

1.1 List of Tables

Table 1: Symptoms of RA 20
Table 2: 1987 ACR Diagnostic Criteria for RA 23
Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA 24
Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM 27
Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity 30
Table 6: EULAR 2013 Criteria for RA Remission 31
Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014 35
Table 8: Leading Branded Treatments for RA 2014 42
Table 9: Unmet Need and Opportunity in RA, 2014 44
Table 10: Comparison of Therapeutic Drug Classes in Development for RA, 2014 62
Table 11: Product Profile - Sarilumab 64
Table 12: MOBILITY Study Part, A, Results for Sarilumab at Week 12 65
Table 13: MOBILITY Study, Part B, Results for Sarilumab at Week 52 65
Table 14: Sarilumab SWOT Analysis, 2014 69
Table 15: Global Sales Forecasts ($m) for Sarilumab, 2013-2023 70
Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 83

1.2 List of Figures

Figure 1: Normal Synovial Joint and Synovial Joint with RA 16
Figure 2: Cellular and Cytokine Targets for the Current RA Drugs 19
Figure 3: Disease Management Flowchart for Early RA - ACR 2012 31
Figure 4: Disease Management Flowchart for Established RA - ACR 2012 32
Figure 5: Flowchart for the Management of RA - EULAR 2013 33
Figure 6: RA - Phase II-III Pipeline, 2014 57
Figure 7: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2013-2023 61
Figure 8: Clinical and Commercial Positioning of Sarilumab 68

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy
Arthritis

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.